← 홈

CGT

121개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 121개
CGTBiologicstaleStanford UniversityPhase 1

GPC2-CAR T cells (GPC2-CAR T cells)

Medulloblastoma; Central Nervous System Embryonal Tumor · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 90%임상시험 1상태 DISCONTINUED
CGTBiologicstaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 50%임상시험 1상태 RECRUITING
CGTBiologicstaleTcelltech Inc.Phase 1

In Vivo CAR-T Therapy (In Vivo CAR-T Therapy)

Relapsed or Refractory Hematologic Malignancies · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleDonghua ZhangPreclinical

Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies (Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies)

Relapsed/Refractory B-cell Malignancies · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleCancer Institute and Hospital, …Phase 1

KSX01-TCRT cell therapy (KSX01-TCRT cell therapy)

Refractory Solid Tumors; Relapsed Solid Tumors · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleNanjing Legend Biotech Co.Phase 1

LUCAR-G79 T cells (LUCAR-G79 T cells)

Relapsed/Refractory Autoimmune Diseases · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

MCARH109 (MCARH109)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

MCARH125 (MCARH125)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleNkarta, Inc.Phase 1

NKX101 - CAR NK cell therapy (NKX101 - CAR NK cell therapy)

Relapsed/Refractory AML; AML, Adult · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleHadassah Medical OrganizationPhase 1

Naive HBI0101 CAR-T (Naive HBI0101 CAR-T)

Relapsed/Refractory Multiple Myeloma (MM) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing GoBroad HospitalPhase 2

New donor-derived CD7 CAR T-cell (New donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing GoBroad HospitalPhase 2

Newly matched donor-derived CD5 CAR T-cells (Newly matched donor-derived CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Newly matched donor-derived FL-33 CAR T therapy (Newly matched donor-derived FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleM.D. Anderson Cancer CenterPhase 2

ONC-PluReceptor NK cells (ONC-PluReceptor NK cells)

Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstalePrecision BioSciences, Inc.Phase 2

PBCAR20A (PBCAR20A)

Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 6%임상시험 1상태 ACTIVE
CGTBiologicstalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED

5 / 7 페이지

← 이전다음 →